NCT05798845View on ClinicalTrials.gov

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
NSCLC
Interventions
RADIATION

SBRT+LDRT

primary tumor SBRT, DT: 24Gy/3Fx, d1-3; positive lymph nodes LDRT, DT: 2Gy/2Fx, d1-2, d22-23 (2 cycles)

DRUG

Toripalimab

toripalimab 240mg ivgtt d4, d24 (2 cycles)

DRUG

Chemotherapy drug

Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum

DRUG

Toripalimab

toripalimab 240mg ivgtt d1, d22 (2 cycles)

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Shanghai Chest Hospital

OTHER